Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of New Nifurtimox Formulation in Chronic Chagas Disease
NCT03708133Phase 1Completed
- Sponsor
- Bayer
- Start
- Dec 2018
- Primary completion
- Apr 2019
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nifurtimox in American trypanosomiasis (CD) (2 arms), sponsored by Bayer. Primary endpoints: Area Under the Plasma Concentration-Time Curve at 15 hours, Area Under the Curve from Time Zero to Last Quantifiable Concentration at 15 hours and 1 more. Started Dec 2018; status: completed.
02
Drugs
nifurtimox
03
Conditions
American trypanosomiasis (CD)
Beyond the preview
Go deeper on NCT03708133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708133.